近期，医药行业利好持续发酵。6月16日，国家药监局发布《关于优化创新药临床试验审评审批有关事项的公 告（征求意见稿）》。其中提到，为进一步支持以临床价值为导向的创新药研发，提高临床研发质效，对符合 要求的创新药临床试验申请在30个工作日内完成审评审批。药物临床试验申请审评审批30日通道支持国家重 点研发品种，鼓励全球早期同步研发和国际多中心临床试验，服务临床急需和国家医药产业发展。 综合自：国家药监局 利好来了。 6月20日，国家药监局党组书记、局长李利主持召开会议，研究部署支持高端医疗器械创新发展举措，审议通 过《关于优化全生命周期监管支持高端医疗器械创新发展的举措》（以下简称《举措》）。 会议指出，党中央、国务院高度重视高端医疗器械创新发展，党的二十届三中全会明确提出要健全支持创新医 疗器械发展机制，2024年，国务院办公厅印发《关于全面深化药品医疗器械监管改革促进医药产业高质量发 展的意见》（国办发〔2024〕53号），提出要深化药品医疗器械监管全过程改革，明确了医疗器械领域支持 要点。医用机器人、高端医学影像设备、人工智能医疗器械和新型生物材料医疗器械等技术集成度高，是高端 医疗器械的典型产品，也是塑 ...

Core Viewpoint - The recent land auction in Sanya, Hainan, where four plots totaling 546.55 acres were sold for approximately 4.4 billion yuan, marks a new high for single-day land sales in the region, with Sanya Fangda Health Investment Co., Ltd. acquiring two plots for 2.875 billion yuan, setting a record for private enterprises in Hainan in 2023 [2][3][4]. Group 1: Land Acquisition Details - The two plots acquired by Sanya Fangda Health Investment cover approximately 286,400 square meters (about 430 acres) and require a total investment of 10 billion yuan within five years [3]. - One plot is designated for residential and commercial use, with a total price of 1.31 billion yuan, while the other is a mixed-use plot including residential, hospital, and commercial spaces, priced at 1.565 billion yuan [3][4]. - The residential portion has a floor area ratio of only 1.2, leading to a sale price of approximately 17,000 yuan per square meter [3]. Group 2: Company Background and Strategy - Sanya Fangda Health Investment was established in May 2023 with a registered capital of 3.5 billion yuan, primarily owned by Liaoning Fangda Group [4]. - Liaoning Fangda Group operates across five major sectors, including carbon products, steel, pharmaceuticals, commerce, and aviation, and has multiple listed companies [4][5]. - The acquisition aligns with the company's strategy to leverage Hainan's free trade port policies and the growing health industry, with plans to invest 5 billion yuan in a health city in Haitang Bay [5]. Group 3: Market Trends and Insights - The land market has seen a rise in private enterprises, with 24 private companies among the top 100 land acquirers in the first five months of 2023, representing 16.8% of total acquisition amounts, an increase from the previous year [6][8]. - New entrants in the market are primarily motivated by the desire to seek development opportunities and improve their asset structures, with many focusing on core regions where they have a deeper understanding of market demands [8]. - Despite the increased willingness of private enterprises to acquire land, the sustainability of this trend remains uncertain, as many acquisitions are opportunistic rather than part of a stable development model [8].

证券研究报告 | 2025年06月20日 高技术制造业宏观周报 国信周频高技术制造业扩散指数保持不变 国信周频高技术制造业扩散指数保持不变。截至 2025 年 6 月 14 日当周， 国信周频高技术制造业扩散指数 A 录得 0；国信周频高技术制造业扩散 指数 B 为 50.8，与上期持平。从分项看，动态随机存储器价格上升，半 导体行业景气度上升；丙烯腈价格下降，航空航天行业景气度下降；6- 氨基青霉烷酸、六氟磷酸锂、中关村电子产品价格指数不变，医药、新 能源、计算机行业景气度不变。 风险提示：高技术制造业发展和结构调整带来指标失灵；经济政策和产业政 策干预；经济增速下滑。 核心观点 经济研究·宏观周报 | 证券分析师：邵兴宇 | 证券分析师：董德志 | | | --- | --- | --- | | 010-88005483 | 021-60933158 | | | shaoxingyu@guosen.com.cndongdz@guosen.com.cn | | | | S0980523070001 | S0980513100001 | | | 基础数据 | | | | 固定资产投资累计同比 | | 3.70 ...

- The report tracks the market trend by monitoring stocks, industries, and sectors that have reached new highs, using a 250-day high distance metric[11][12][13] - The 250-day high distance is calculated as: $ 250 \text{ day high distance} = 1 - \frac{Closet}{ts\_max(Close, 250)} $ where Closet is the latest closing price and $ ts\_max(Close, 250) $ is the maximum closing price in the past 250 trading days[11] - As of June 20, 2025, the 250-day high distances for major indices are: Shanghai Composite Index 3.72%, Shenzhen Component Index 12.96%, CSI 300 9.62%, CSI 500 10.92%, CSI 1000 9.26%, CSI 2000 7.07%, ChiNext Index 21.19%, and STAR 50 Index 14.99%[2][12][13] - The report identifies 816 stocks that reached a 250-day high in the past 20 trading days, with the highest numbers in the pharmaceutical, basic chemicals, and machinery industries[3][19][20] - The report also tracks "stable new high stocks" based on analyst attention, relative stock strength, trend continuity, price path stability, and new high sustainability, selecting 26 stocks such as Sijia Photon, Shenghong Technology, and Boryung Pharmaceutical[3][25][27] - The selected stable new high stocks are mainly from the financial and cyclical sectors, with the financial sector having the most new highs in the banking industry and the cyclical sector in the basic chemicals industry[3][28][29]

Core Insights - The article narrates the evolution of Woming Investment, a firm focused on the healthcare sector, founded by Zhang Yingjie ten years ago, highlighting the shift from speculative to long-term investment strategies in the Chinese pharmaceutical industry [2][3][4] Group 1: Company Evolution - Woming Investment was established on June 1, 2015, during a transformative period for China's pharmaceutical industry, marked by significant reforms and innovations [3][4] - The firm initially focused on Pre-IPO investments but later recognized the limitations of this approach, leading to a broader strategy encompassing angel investments, venture capital, growth-stage investments, and mergers and acquisitions [9][10] - A pivotal investment was made in Push Pharmaceutical, which faced challenges that prompted a strategic shift in Woming's operational approach, emphasizing hands-on management and long-term value creation [10][11][15] Group 2: Investment Strategy Shift - The firm transitioned from a purely financial investor to a model that integrates operational involvement, reflecting a broader trend in the Chinese venture capital landscape [6][7][8] - Woming's investment philosophy evolved to prioritize long-term operational improvements over quick financial returns, focusing on enhancing research and sales capabilities [18][19] - The firm’s approach is characterized by a commitment to working closely with portfolio companies, fostering a collaborative environment to build value over time [20][24] Group 3: Industry Context - The Chinese biopharmaceutical sector has seen substantial capital inflow, with over 1.23 trillion yuan raised for innovative drugs from 2015 to 2024, indicating a robust investment climate [8] - The number of publicly listed pharmaceutical companies in China has significantly increased, from 214 in 2015 to 516 by the end of 2024, reflecting the industry's growth [8] - Despite the overall positive investment climate, the article notes that the market has matured, making it increasingly challenging to achieve high returns, particularly in the biopharmaceutical sector [27][28]

Summary of Key Points Core Viewpoint - The company plans to provide a guarantee of up to RMB 150 million for its wholly-owned subsidiaries, Shanghai Yahuang and Hainan Yahuang, to meet their funding needs for business operations, which represents 7.62% of the company's latest audited net assets [1][6]. Group 1: Guarantee Details - The guarantee will be in the form of joint liability guarantee and the specific terms will be defined in the actual guarantee contract [6]. - The board of directors approved the guarantee proposal on June 20, 2025, and it does not require submission to the shareholders' meeting for approval [1][6]. Group 2: Subsidiary Information - Shanghai Yahuang was established on November 17, 2017, with a registered capital of RMB 50 million and is 100% owned by the company [3]. - Hainan Yahuang was established on March 17, 2022, with a registered capital of RMB 10 million and is also 100% owned by the company [4][5]. Group 3: Financial Data - Shanghai Yahuang's total assets are RMB 317.45 million, total liabilities are RMB 975.44 million, and net assets are -RMB 657.99 million, with a revenue of RMB 0.0197 million and a net loss of RMB 204.81 million [2]. - Hainan Yahuang's total assets are RMB 107.26 million, total liabilities are RMB 157.27 million, and net assets are -RMB 50.01 million, with a revenue of RMB 174.98 million and a net loss of RMB 40.97 million [5]. Group 4: Rationale for Guarantee - The guarantee is intended to enhance the financing efficiency of the subsidiaries, ensuring their operational needs are met and aligning with the overall interests of the company [6]. - The company maintains absolute control over its subsidiaries, allowing for effective monitoring of their operations and financial usage, thus keeping the guarantee risk manageable [6]. Group 5: Board and Sponsor Opinions - The board believes that the guarantee aligns with the operational needs of the company and its subsidiaries, poses controllable risks, and does not harm the interests of the company or minority shareholders [6]. - The sponsor has confirmed that the decision-making process for the guarantee complies with relevant regulations and does not harm the interests of the company and its shareholders [7][8].

Group 1: Institutional Trading Insights - On the institutional trading leaderboard, 28 stocks were listed, with 16 experiencing net buying and 13 facing net selling [1] - The top three stocks with the highest institutional buying were: Limin Co., Ltd. (75.16 million), Saiseng Pharmaceutical (71.78 million), and Haike Xinyuan (37.08 million) [1] Group 2: Stock Performance and Market Trends - Limin Co., Ltd. saw a decrease of 9.98% with a net buying amount of 105 million [2] - Saiseng Pharmaceutical experienced a significant increase of 19.97% with a net buying amount of 57.49 million [2] - Haike Xinyuan had a notable rise of 20.00% with a net buying amount of 37.09 million [2] Group 3: Industry Developments - Saiseng Pharmaceutical's subsidiary, Junyuan Pharmaceutical, produces ursodeoxycholic acid tablets, indicating a focus on relevant production capabilities [3] - The solid-state battery sector is advancing, with companies like Kexin and Taiblue New Energy developing new materials and products for battery applications [3] - The Ministry of Industry and Information Technology is expected to conduct a mid-term review of solid-state battery projects by the end of 2025, with key developments anticipated between 2025 and 2026 [3] Group 4: Market Opportunities in Advanced Packaging - The advanced packaging market is projected to grow from 30.4 billion in 2020 to approximately 47.5 billion by 2026, increasing its market share from 45% to 50% [5]

东 兴 晨 报 东兴晨报 P1 2025 年 6 月 20 日星期五 经济要闻 1. 商务部：将依法依规不断加快对稀土相关出口许可申请的审查。在 19 日商务部举行的例行发布会上，新闻发言人何亚东谈到稀土相关出口问题时 表示，将依法依规不断加快对稀土相关出口许可申请的审查。商务部新闻发 言人何亚东表示，中国一贯高度重视维护全球产供链的稳定与安全，依法依 规不断加快对稀土相关出口许可申请的审查，已经依法批准一定数量的合规 申请，并将持续加强合规申请的审批工作。中方愿就此进一步加强与相关国 家的出口管制沟通对话，积极促进便利合规贸易。（资料来源：同花顺，央视 新闻） 2. 商务部：商务部召开例行新闻发布会，有记者就中欧经贸关系提问。商 务部新闻发言人何亚东：中欧互为主要贸易伙伴，中方高度重视中欧经贸关 系，一直与欧方保持各层级的密切沟通，推动双边贸易投资合作健康、稳定 发展，加强在世贸组织等多边领域的立场协调，致力于通过对话协商来妥善 解决经贸摩擦。今年是中国与欧盟建交五十周年。中方将与欧方一道，全面 落实双方领导人达成的重要共识，积极推动中欧经贸合作提质升级，推动解 决彼此关切，共同为中欧高层交往做好经贸议题和 ...

【导读】德勤：上半年香港新股融资总额 料 同比攀升673% 中国基金报记者 郭玟君 6月 19日， 德勤中国资本市场服务部发布2025年中国内地和香港新股市场的中期回顾与展 望。 德勤预计， 2 025年上半年，香港 上市的 40只新股 合计 融资 额将达 1021亿港元。去年 同期，香港市场上市 30只新股，合计 融资132亿港元。 2025年上半年， 新股上市数量增加 33%，融资总额攀升673%。2025年上半年的融资额 约25% 来自4只超大型A+H新股及1只 H股上市。 德勤表示，目前香港有超过170宗正在处理的上市申请个案。 其中 5家公司每家或 至少 融资 10亿美元。德勤中国资本市场服务部预计，2025年全年，香港新股市场可 有 80只新股，新 股合计 融资 额或达 2000亿港元。年内或录得25只A+H新股。 此外， 大部分上市项目将会 来自科技、传媒和电信，以及消费业。 版权声明 《中国基金报》对本平台所刊载的原创内容享有著作权，未经授权禁止转载，否则将追究法律责任。 授权转载合作联系人：于先生（电话：0755-82468670） 德勤表示， 2025年上半年， A股市场 或 将有50只新 ...

Group 1 - President Xi Jinping emphasized the urgency of a ceasefire in the Middle East, stating that the use of force is not the correct way to resolve international disputes [1] - The Chinese photovoltaic industry is expected to see a significant production cut in Q3, with operating rates projected to decrease by 10%-15% [1] - The Ministry of Commerce announced it will expedite the review of export license applications related to rare earths, aiming to maintain global supply chain stability [1] Group 2 - The China Securities Index will officially launch the China Science and Technology Innovation Semiconductor Index on June 20, 2025, which will include 50 companies from the STAR Market and ChiNext [2] - The Ministry of Commerce highlighted the importance of China-EU economic and trade relations, emphasizing ongoing communication and cooperation [2] Group 3 - Kweichow Moutai announced a cash dividend of 27.673 yuan per share for the 2024 fiscal year, totaling 34.671 billion yuan [3] - Zhongqi New Materials reported that Starry Sky Technology has become its controlling shareholder [3] - Lianchuang Optoelectronics noted strong demand for drone countermeasure equipment in the Middle East [3] Group 4 - Fuhuang Steel Structure announced the termination of its plan to issue shares and pay cash for asset purchases [4] - Shengnuo Bio expects a significant increase in net profit for the first half of the year, projecting a year-on-year growth of 254%-332% [4] Group 5 - Zhongyan Chemical plans to agree to a capital reduction for Zhongyan Alkali Industry, which is expected to constitute a major asset restructuring [5] - Kanda New Materials intends to acquire at least 51% of Zhongke Huamei's shares to expand into the semiconductor integrated circuit field [6] Group 6 - Times Publishing clarified that it does not engage in stablecoin business and has a minimal indirect stake in JD Technology [8] - Sanhua Intelligent Controls confirmed the final price for its H-share issuance at 22.53 HKD per share [9] Group 7 - Taiji Co. announced that Changjiang Industrial Group will become its indirect controlling shareholder, with stock resuming trading on June 20, 2025 [10] - Guosen Securities received approval from the Shenzhen Stock Exchange for its acquisition of 96.08% of Wanhe Securities [10] Group 8 - Zhongsheng Pharmaceutical completed the first participant enrollment for its Phase III clinical trial of the innovative drug RAY1225 for obesity [11] - Yuncong Technology stated that its multi-modal AI technology for live detection can be applied to stablecoin wallet scenarios [12]